The mechanism of action of Platinib_Kain Industrial Additives

background and overview[1] with the development and application of tyrosine kinase inhibitors (tkis), the clinical outcomes of patients with chronic myelogenous leukemia (cml) and urban chromosome-positive acute lymphoblastic leukemia (ph+all) have been significantly improved. imatinib mesylate is the first first-generation tkis approved for marketing in the world. it can specifically block the binding position of…